Home ›
Entities
› academia
› Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study
Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study
Research article (Korean Journal of Radiology, 2022) · cited 23× · AI/ML
Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study
Summary
Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study is a scholarly article[1].
Key Facts
Sonazoid™ versus SonoVue® for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. Retrieved May 24, 2026, from https://4ort.xyz/entity/sonazoidtm-versus-sonovue-sup-sup-for-diagnosing-hepatocellular-carcinoma-using-contrast-enhanced-ultrasound-in-at-risk-
MLA“Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/sonazoidtm-versus-sonovue-sup-sup-for-diagnosing-hepatocellular-carcinoma-using-contrast-enhanced-ultrasound-in-at-risk-.
BibTeX@misc{4ortxyz_sonazoidtm-versus-sonovue-sup-sup-for-diagnosing-hepatocellular-carcinoma-using-contrast-enhanced-ultrasound-in-at-risk-_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study}}, year = {2026}, url = {https://4ort.xyz/entity/sonazoidtm-versus-sonovue-sup-sup-for-diagnosing-hepatocellular-carcinoma-using-contrast-enhanced-ultrasound-in-at-risk-}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study — https://4ort.xyz/entity/sonazoidtm-versus-sonovue-sup-sup-for-diagnosing-hepatocellular-carcinoma-using-contrast-enhanced-ultrasound-in-at-risk- (retrieved 2026-05-24)
